A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...
Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...
The Program Committee of the AUA has accepted the Theralase®'s abstract titled: ' Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive ...
Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).
TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...
"Patients with BCG-naïve high-risk non-muscle invasive bladder cancer have high rates of recurrence and progression," said Neal Shore, M.D., FACS, Medical Director for the Carolina Urologic ...
ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...
Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...